US › Healthcare

Elicio Therapeutics Inc. (ELTX)

US · Healthcare · Biotechnology

$3.16+10.49%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-11.8M
Profit YoY
-5.5%
EPS
$-0.65
EPS estimate
$-0.46

EPS came in at -0.65 against a street estimate of -0.46 — a miss of 41.3%.

Key statistics

Market cap
$75.1M
Forward P/E
0.0
P/B
132.74
Book value
$-0.08
EPS (TTM)
$-2.36
52-week high
$16.00
52-week low
$2.66
50-day MA
$6.41
200-day MA
$8.83
Beta
1.88

Analyst view

Analysts rate Elicio Therapeutics Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $20.00.

Shareholding

Insiders
30.80%
Institutions
17.33%

Largest institutional holders

FundStake
Knoll Capital Management LP3.31%
Vanguard Capital Management, LLC2.72%
Vanguard Group Inc2.60%
Balyasny Asset Management LLC1.28%
Geode Capital Management, LLC0.71%
Renaissance Technologies Corp0.64%
Millennium Management LLC0.49%
Marshall Wace Asset Management Ltd0.39%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Elicio Therapeutics Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.